GPT and Hypertension: The rates of treatment-related adverse events of grade 3 or higher were 60.6% (6.9% diarrhea, 7.5% PPES, 12.5% hypertension, 5.3% increased ALT level, 9.4% hyponatremia, 5.9% hypophosphatemia) in the nivolumab-plus-cabozantinib group and 50.9% (4.4% diarrhea, 7.5% PPES, 13.1% hypertension, 4.7% decreased platelet count and 3.8% neutropenia/anemia) in the sunitinib group.